Publications




To see a full list of publications please go to Greg's UCL IRIS page and click the publications tab or Greg's Google Scholars link.

Left: Cover of Nature Structural and Molecular Biology referencing Price et al, 2009. Right: Figure 1A from Towers GJ, Retrovirology 2007.



Cover referencing Price et al, 2009




Favourites


Rasaiyaah, J., C. P. Tan, A. J. Fletcher, A. J. Price, C. Blondeau, L. Hilditch, D. A. Jacques, D. L. Selwood, L. C. James, M. Noursadeghi and G. J. Towers. 2013. HIV-1 evades innate immune recognition through specific co-factor recruitment. Nature (2013) doi:10.1038/nature12769

Blondeau, C., A. Pelchen-Matthews, P. Mlcochova, M. Marsh, R. S. Milne, and G. J. Towers. 2013. Tetherin Restricts Herpes Simplex Virus Type 1 and is Antagonised by Glycoprotein M. J Virol. 2013 Sep 25

Bichel, K., A. J. Price, T. Schaller, G. J. Towers, S. M. Freund, and L. C. James. 2013. HIV-1 capsid undergoes coupled binding and isomerization by the nuclear pore protein NUP358. Retrovirology 10:81.

Price, A. J., A. J. Fletcher, T. Schaller, T. Elliot, K. Lee, V. N. Kewalramani, J. Chin, G. J. Towers, and L. C. James. 2012. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS pathogens 8:e1002896

Schaller, T., K. E. Ocwieja, J. Rasaiyaah, A. J. Price, T. L. Brady, S. L. Roth, S. Hue, A. J. Fletcher, K. Lee, V. N. Kewalramani, M. Noursadeghi, R. G. Jenner, L. C. James, F. D. Bushman, and G. J. Towers. 2011. HIV-1 Capsid-Cyclophilin Interactions Determine Nuclear Import Pathway, Integration Targeting and Replication Efficiency. PLoS Pathog 7:e1002439

Hué S, Gray ER, Gall A, Katzourakis A, Tan CP, Houldcroft CJ, McLaren S, Pillay D, Futreal A, Garson JA, Pybus OG, Kellam P, Towers GJ. 2010. Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology 7:111.

Ylinen, L. M., Price, A. J., Rasaiyaah, J., Hue, S., Rose, N. J., Marzetta, F., James, L. C. & Towers, G. J. 2010. Conformational Adaptation of Asian Macaque TRIMCyp Directs Lineage Specific Antiviral Activity. PLoS Pathogens 6: e1001062

Mallery, D. L., W. A. McEwan, S. R. Bidgood, G. J. Towers, C. M. Johnson, and L. C. James. 2010. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proceedings of the National Academy of Sciences of the United States of America 107:19985-19990.

Price, A. J., F. Marzetta, M. Lammers, L. M. J. Ylinen, T. Schaller, S. J. Wilson, G. J. Towers* and L. C. James*. 2009. Active site remodelling switches HIV specificity of antiretroviral TRIMCyp. Nature Struct Mol Biol 16: 1036-42 * Corresponding Authors

Gupta, K. R., S. Hué, T. Schaller, E. Verschoor, D. Pillay and G. J. Towers. 2009. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PloS Pathogens 5:e1000443

Wilson, S. J., Webb, B. L. J, Ylinen, L. M. J., Verschoor, E., Heeney, J. L., and G. J. Towers. 2008 Independent evolution of an antiviral TRIMCyp in Rhesus Macaques Proc Natl Acad Sci USA. 105: 35507-62

Keckesova, Z., Ylinen, L. M. J. Towers, G. J. 2004. The human and African green monkey TRIM5a genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci USA 101: 10780-5

Towers, G. J., Hatziioannou, T., Cowan, S., Goff, S. P., Luban, J., and Bieniasz, P. D. 2003. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nature Med 9: 1138-43

Best, S., Le Tissier, P., Towers, G, Stoye, J. P. 1996. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 382: 826-829

Page last modified on 12 nov 13 18:29 by Jane Lorna Elizabeth Turner